Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response.
Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response.
复制标题
DOI：
10.1016/j.leukres.2012.02.011
复制
发表时间：
2012-06
影响因子：
2.7
通讯作者：
H. Yhim;N. Lee;E. Song;C. Yim;S. Jeon;Seung-Hwan Shin;Jeong-A Kim;Hee Sun Kim;Eun Hae Cho;J. Kwak
中科院分区：
文献类型：
--
作者：
H. Yhim;N. Lee;E. Song;C. Yim;S. Jeon;Seung-Hwan Shin;Jeong-A Kim;Hee Sun Kim;Eun Hae Cho;J. Kwak
